非ST段抬高型急性冠状动脉综合征患者应用国产替罗非班的疗效观察

Clinical study of domestic tirofiban in patients with non-ST-segment elevation acute coronary syndrome(NSTE-ACS)

目的评价国产替罗非班对非ST段抬高型急性冠状动脉综合征(NSTE-ACS)患者的疗效与安全性。方法 150例拒绝经皮冠状动脉内介入治疗(PCI)的NSTE-ACS患者随机分为替罗非班组和对照组。观察2组患者再发心绞痛、心肌梗死以及心源性猝死、皮肤黏膜出血等情况,并评价肌钙蛋白(cTnT)、B型钠尿肽(BNP)、血小板抑制率。结果替罗非班组48 h终点事件发生率明显低于对照组,2组之间出血并发症发生率无显著性差异。2组患者治疗后cTnT、BNP水平均较治疗前明显降低,而替罗非班组降低程度明显高于对照组,替罗非班组血小板抑制率明显高于对照组。结论国产替罗非班在NSTE-ACS患者治疗中可有效减少心脏事件、改善预后,不增加出血风险。

Objective To evaluate the effect and safety of domestic tirofiban in NSTE-ACS patients.Methods One hundred and fifty NSTE-ACS patients who refused the treatment of PCI treatment were divided into tirofiban group and control group（conventional therapy）.The events of recurrent angina,myocardial infarction and cardiogenic sudden death,mucocutaneous bleeding and the changes of BNP,cTnT,platelet inhibition rate level before and after treatment were observed.Results Compared with the control group,tirofiban group had a significant lower 48 h end event rate.There was no significant difference in bleeding complications between the two groups.The level of cTnT and BNP were significantly decreased after treatment,and the effect of the tirofiban group was better than that of the control group.Platelet aggregation rate in tirofiban group was significantly higher than that of the control group.Conclusion Domestic tirofiban has good effect and tolerance for patients with NSTE-ACS,meanwhile it does not increase hemorrhage risk.